CytoViva

Executive Summary

CytoViva, Inc. is a privately-held company based in Auburn, Alabama, specializing in advanced optical microscopy and hyperspectral imaging technologies. Founded in 2004, the company develops patented enhanced darkfield microscopy and hyperspectral imaging systems that enable researchers to observe and spectrally characterize nanoscale elements in biological tissues, materials, and other environments. Their solutions are tailored for nanomaterials research, pathogen detection, and general biology applications, providing high-resolution imaging without the need for fluorescent labels. CytoViva's technology bridges the gap between conventional microscopy and electron microscopy, offering a unique capability for real-time nanoscale observation in wet or dry samples. With a focus on serving academic, government, and industrial research laboratories, CytoViva has established a niche in the life sciences and materials science markets. The company's products are used in diverse fields such as nanotoxicology, drug delivery, microbiology, and environmental monitoring. As the demand for advanced imaging tools grows, particularly in infectious disease research and nanomedicine, CytoViva is well-positioned to expand its market share. Potential upcoming catalysts include product enhancements, strategic collaborations, and regulatory clearances that could accelerate adoption and drive revenue growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation hyperspectral imaging system with enhanced sensitivity70% success
• Q4 2026Strategic partnership with a major pharmaceutical company for drug delivery and nanotoxicology research60% success
• Q2 2027FDA 510(k) clearance for a diagnostic application using CytoViva imaging for pathogen detection50% success